The agreement covers distribution of an antibiotic effective against MRSA across the Middle East and North African region
Hikma Pharmaceuticals has announced an exclusive licence, supply and distribution agreement with the American company, Melinta Therapeutics. The deal encompasses Melinta’s intravenous and oral formulations of the antibiotic, Baxdela (delafloxacin), across all Middle Eastern and North Africa (MENA) markets.
The UK-based Hikma also has the right of first negotiation for all other products in Melinta’s portfolio and pipeline in the region.
Baxdela is an antibiotic product used for the treatment of adult patients with acute bacterial skin and skin structure infections. It is a fluoroquinolone with demonstrated efficacy against both gram-positive and gram-negative pathogens, including MRSA (methicillin-resistant Staphylococcus aureus). Baxdela was approved by the US FDA in 2017.
Hikma offers a range of antibiotic products to doctors and pharmacists in the MENA region. As antimicrobial resistance continues to pose treatment challenges for healthcare professionals, offering this new product in the region will arm them with new ways to combat this growing threat.
Mazen Darwazah, Executive Vice Chairman and President of MENA, said: “We are very pleased to establish a partnership with Melinta and to be able to bring this innovative product to the region. As the challenge of antimicrobial resistance grows, we have an important role to play in helping to equip doctors here in MENA with the latest and most innovative developments.”